| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | chromatin binding | 4.70e-06 | 739 | 20 | 7 | GO:0003682 | |
| GeneOntologyMolecularFunction | transcription coactivator activity | 1.00e-05 | 303 | 20 | 5 | GO:0003713 | |
| GeneOntologyMolecularFunction | transcription coregulator activity | 1.89e-04 | 562 | 20 | 5 | GO:0003712 | |
| GeneOntologyMolecularFunction | RNA polymerase II transcription regulatory region sequence-specific DNA binding | 3.64e-04 | 1459 | 20 | 7 | GO:0000977 | |
| GeneOntologyMolecularFunction | nuclear thyroid hormone receptor binding | 5.25e-04 | 34 | 20 | 2 | GO:0046966 | |
| GeneOntologyMolecularFunction | protein phosphatase 2A binding | 8.01e-04 | 42 | 20 | 2 | GO:0051721 | |
| GeneOntologyMolecularFunction | RNA polymerase II cis-regulatory region sequence-specific DNA binding | 1.05e-03 | 1244 | 20 | 6 | GO:0000978 | |
| GeneOntologyMolecularFunction | cis-regulatory region sequence-specific DNA binding | 1.17e-03 | 1271 | 20 | 6 | GO:0000987 | |
| GeneOntologyMolecularFunction | nuclear estrogen receptor binding | 1.27e-03 | 53 | 20 | 2 | GO:0030331 | |
| GeneOntologyMolecularFunction | nuclear receptor coactivator activity | 1.68e-03 | 61 | 20 | 2 | GO:0030374 | |
| GeneOntologyMolecularFunction | DNA-binding transcription factor activity, RNA polymerase II-specific | 2.02e-03 | 1412 | 20 | 6 | GO:0000981 | |
| GeneOntologyMolecularFunction | DNA-binding transcription activator activity, RNA polymerase II-specific | 2.07e-03 | 560 | 20 | 4 | GO:0001228 | |
| GeneOntologyMolecularFunction | DNA-binding transcription activator activity | 2.16e-03 | 566 | 20 | 4 | GO:0001216 | |
| GeneOntologyMolecularFunction | protein-macromolecule adaptor activity | 4.89e-03 | 1160 | 20 | 5 | GO:0030674 | |
| GeneOntologyMolecularFunction | transcription factor binding | 6.00e-03 | 753 | 20 | 4 | GO:0008134 | |
| GeneOntologyMolecularFunction | RNA polymerase II-specific DNA-binding transcription factor binding | 7.92e-03 | 417 | 20 | 3 | GO:0061629 | |
| GeneOntologyBiologicalProcess | positive regulation of transcription by RNA polymerase II | 9.85e-08 | 1390 | 19 | 10 | GO:0045944 | |
| GeneOntologyBiologicalProcess | positive regulation of intracellular steroid hormone receptor signaling pathway | 5.36e-07 | 18 | 19 | 3 | GO:0033145 | |
| GeneOntologyBiologicalProcess | positive regulation of intracellular estrogen receptor signaling pathway | 5.28e-05 | 12 | 19 | 2 | GO:0033148 | |
| GeneOntologyBiologicalProcess | regulation of intracellular steroid hormone receptor signaling pathway | 6.69e-05 | 87 | 19 | 3 | GO:0033143 | |
| GeneOntologyBiologicalProcess | neuron fate commitment | 7.65e-05 | 91 | 19 | 3 | GO:0048663 | |
| GeneOntologyBiologicalProcess | cell fate commitment | 2.26e-04 | 338 | 19 | 4 | GO:0045165 | |
| GeneOntologyBiologicalProcess | dorsal/ventral neural tube patterning | 2.38e-04 | 25 | 19 | 2 | GO:0021904 | |
| GeneOntologyBiologicalProcess | nuclear receptor-mediated steroid hormone signaling pathway | 2.51e-04 | 136 | 19 | 3 | GO:0030518 | |
| GeneOntologyBiologicalProcess | cerebral cortex neuron differentiation | 3.22e-04 | 29 | 19 | 2 | GO:0021895 | |
| GeneOntologyBiologicalProcess | steroid hormone receptor signaling pathway | 3.69e-04 | 155 | 19 | 3 | GO:0043401 | |
| GeneOntologyBiologicalProcess | positive regulation of cell differentiation | 4.11e-04 | 1141 | 19 | 6 | GO:0045597 | |
| GeneOntologyBiologicalProcess | cellular response to hormone stimulus | 4.13e-04 | 727 | 19 | 5 | GO:0032870 | |
| GeneOntologyBiologicalProcess | regulation of intracellular estrogen receptor signaling pathway | 4.97e-04 | 36 | 19 | 2 | GO:0033146 | |
| GeneOntologyBiologicalProcess | neural tube patterning | 7.77e-04 | 45 | 19 | 2 | GO:0021532 | |
| GeneOntologyBiologicalProcess | nuclear receptor-mediated signaling pathway | 7.99e-04 | 202 | 19 | 3 | GO:0141193 | |
| GeneOntologyBiologicalProcess | regionalization | 8.37e-04 | 478 | 19 | 4 | GO:0003002 | |
| GeneOntologyBiologicalProcess | Notch signaling pathway | 8.94e-04 | 210 | 19 | 3 | GO:0007219 | |
| GeneOntologyBiologicalProcess | central nervous system neuron differentiation | 9.83e-04 | 217 | 19 | 3 | GO:0021953 | |
| GeneOntologyBiologicalProcess | mRNA transcription by RNA polymerase II | 1.04e-03 | 52 | 19 | 2 | GO:0042789 | |
| GeneOntologyBiologicalProcess | chromatin organization | 1.07e-03 | 896 | 19 | 5 | GO:0006325 | |
| GeneOntologyBiologicalProcess | chordate embryonic development | 1.12e-03 | 906 | 19 | 5 | GO:0043009 | |
| GeneOntologyBiologicalProcess | pattern specification process | 1.19e-03 | 526 | 19 | 4 | GO:0007389 | |
| GeneOntologyBiologicalProcess | estrogen receptor signaling pathway | 1.24e-03 | 57 | 19 | 2 | GO:0030520 | |
| GeneOntologyBiologicalProcess | mRNA transcription | 1.24e-03 | 57 | 19 | 2 | GO:0009299 | |
| GeneOntologyBiologicalProcess | embryo development ending in birth or egg hatching | 1.26e-03 | 929 | 19 | 5 | GO:0009792 | |
| GeneOntologyBiologicalProcess | stem cell population maintenance | 1.27e-03 | 237 | 19 | 3 | GO:0019827 | |
| GeneOntologyBiologicalProcess | cellular response to steroid hormone stimulus | 1.30e-03 | 239 | 19 | 3 | GO:0071383 | |
| GeneOntologyBiologicalProcess | positive regulation of leukocyte differentiation | 1.35e-03 | 242 | 19 | 3 | GO:1902107 | |
| GeneOntologyBiologicalProcess | maintenance of cell number | 1.35e-03 | 242 | 19 | 3 | GO:0098727 | |
| GeneOntologyBiologicalProcess | positive regulation of hemopoiesis | 1.35e-03 | 242 | 19 | 3 | GO:1903708 | |
| GeneOntologyBiologicalProcess | hormone-mediated signaling pathway | 1.38e-03 | 244 | 19 | 3 | GO:0009755 | |
| GeneOntologyBiologicalProcess | Rac protein signal transduction | 1.38e-03 | 60 | 19 | 2 | GO:0016601 | |
| GeneOntologyBiologicalProcess | cellular response to oxygen-containing compound | 1.46e-03 | 1450 | 19 | 6 | GO:1901701 | |
| GeneOntologyBiologicalProcess | protein-DNA complex organization | 1.74e-03 | 999 | 19 | 5 | GO:0071824 | |
| GeneOntologyBiologicalProcess | response to hormone | 2.09e-03 | 1042 | 19 | 5 | GO:0009725 | |
| GeneOntologyBiologicalProcess | skeletal system development | 2.12e-03 | 615 | 19 | 4 | GO:0001501 | |
| GeneOntologyBiologicalProcess | cellular response to oxidative stress | 2.37e-03 | 295 | 19 | 3 | GO:0034599 | |
| GeneOntologyBiologicalProcess | stem cell differentiation | 2.63e-03 | 306 | 19 | 3 | GO:0048863 | |
| GeneOntologyCellularComponent | chromatin | 3.00e-04 | 1480 | 20 | 7 | GO:0000785 | |
| HumanPheno | Alveolar rhabdomyosarcoma | 1.62e-05 | 5 | 7 | 2 | HP:0006779 | |
| Domain | DUF4927 | 1.09e-06 | 2 | 20 | 2 | IPR032565 | |
| Domain | DUF4927 | 1.09e-06 | 2 | 20 | 2 | PF16279 | |
| Domain | DUF1518 | 3.27e-06 | 3 | 20 | 2 | SM01151 | |
| Domain | Nuc_rcpt_coact_Ncoa-typ | 3.27e-06 | 3 | 20 | 2 | IPR014920 | |
| Domain | SRC-1 | 3.27e-06 | 3 | 20 | 2 | IPR014935 | |
| Domain | SRC-1 | 3.27e-06 | 3 | 20 | 2 | PF08832 | |
| Domain | DUF1518 | 3.27e-06 | 3 | 20 | 2 | PF07469 | |
| Domain | - | 3.27e-06 | 3 | 20 | 2 | 4.10.630.10 | |
| Domain | DUF1518 | 3.27e-06 | 3 | 20 | 2 | IPR010011 | |
| Domain | Nuc_rec_co-act | 3.27e-06 | 3 | 20 | 2 | PF08815 | |
| Domain | Src1_rcpt_coact | 3.27e-06 | 3 | 20 | 2 | IPR008955 | |
| Domain | Nuclear_rcpt_coactivator | 3.27e-06 | 3 | 20 | 2 | IPR017426 | |
| Domain | Nuc_rcpt_coact | 1.63e-05 | 6 | 20 | 2 | IPR009110 | |
| Domain | PAS | 3.22e-04 | 25 | 20 | 2 | PF00989 | |
| Domain | PAS_fold | 3.22e-04 | 25 | 20 | 2 | IPR013767 | |
| Domain | PAS | 5.30e-04 | 32 | 20 | 2 | SM00091 | |
| Domain | PAS | 5.99e-04 | 34 | 20 | 2 | IPR000014 | |
| Domain | PAS | 5.99e-04 | 34 | 20 | 2 | PS50112 | |
| Domain | TF_fork_head_CS_2 | 1.10e-03 | 46 | 20 | 2 | IPR030456 | |
| Domain | TF_fork_head_CS_1 | 1.14e-03 | 47 | 20 | 2 | IPR018122 | |
| Domain | FORK_HEAD_3 | 1.24e-03 | 49 | 20 | 2 | PS50039 | |
| Domain | FH | 1.24e-03 | 49 | 20 | 2 | SM00339 | |
| Domain | FORK_HEAD_1 | 1.24e-03 | 49 | 20 | 2 | PS00657 | |
| Domain | FORK_HEAD_2 | 1.24e-03 | 49 | 20 | 2 | PS00658 | |
| Domain | Forkhead | 1.24e-03 | 49 | 20 | 2 | PF00250 | |
| Domain | Fork_head_dom | 1.24e-03 | 49 | 20 | 2 | IPR001766 | |
| Domain | - | 1.54e-03 | 218 | 20 | 3 | 1.10.10.10 | |
| Domain | WHTH_DNA-bd_dom | 2.08e-03 | 242 | 20 | 3 | IPR011991 | |
| Domain | - | 5.99e-03 | 109 | 20 | 2 | 4.10.280.10 | |
| Domain | HLH | 6.75e-03 | 116 | 20 | 2 | SM00353 | |
| Domain | BHLH | 6.87e-03 | 117 | 20 | 2 | PS50888 | |
| Domain | bHLH_dom | 6.98e-03 | 118 | 20 | 2 | IPR011598 | |
| Domain | SH3_1 | 1.31e-02 | 164 | 20 | 2 | PF00018 | |
| Pathway | WP_PREGNANE_X_RECEPTOR_PATHWAY | 8.47e-06 | 32 | 18 | 3 | M39567 | |
| Pathway | WP_ENDODERM_DIFFERENTIATION | 2.78e-05 | 143 | 18 | 4 | M39591 | |
| Pathway | WP_EGFEGFR_SIGNALING | 4.54e-05 | 162 | 18 | 4 | M39334 | |
| Pathway | KEGG_MEDICUS_REFERENCE_NUCLEAR_INITIATED_ESTROGEN_SIGNALING_PATHWAY | 8.41e-05 | 11 | 18 | 2 | M47503 | |
| Pathway | WP_HYPOXIADEPENDENT_SELFRENEWAL_OF_MYOBLASTS | 1.39e-04 | 14 | 18 | 2 | MM15832 | |
| Pathway | PID_SMAD2_3NUCLEAR_PATHWAY | 1.45e-04 | 82 | 18 | 3 | M2 | |
| Pathway | PID_ERB_GENOMIC_PATHWAY | 1.60e-04 | 15 | 18 | 2 | M119 | |
| Pathway | WP_RUBINSTEINTAYBI_SYNDROME_1 | 1.60e-04 | 15 | 18 | 2 | M48323 | |
| Pathway | REACTOME_DEVELOPMENTAL_BIOLOGY | 1.91e-04 | 1432 | 18 | 8 | M509 | |
| Pathway | WP_ANDROGEN_RECEPTOR_SIGNALING | 1.98e-04 | 91 | 18 | 3 | M39700 | |
| Pathway | WP_FOXA2_PATHWAY | 3.19e-04 | 21 | 18 | 2 | M42579 | |
| Pathway | REACTOME_GASTRULATION | 5.52e-04 | 129 | 18 | 3 | M46433 | |
| Pathway | PID_RETINOIC_ACID_PATHWAY | 6.56e-04 | 30 | 18 | 2 | M207 | |
| Pathway | WP_CONSTITUTIVE_ANDROSTANE_RECEPTOR_PATHWAY | 7.01e-04 | 31 | 18 | 2 | M39476 | |
| Pathway | REACTOME_ESTROGEN_DEPENDENT_GENE_EXPRESSION | 8.40e-04 | 149 | 18 | 3 | M27888 | |
| Pathway | WP_MESODERMAL_COMMITMENT_PATHWAY | 9.08e-04 | 153 | 18 | 3 | M39546 | |
| Pathway | REACTOME_REGULATION_OF_BETA_CELL_DEVELOPMENT | 1.29e-03 | 42 | 18 | 2 | M17541 | |
| Pathway | WP_IL7_SIGNALING_PATHWAY | 1.35e-03 | 43 | 18 | 2 | MM15864 | |
| Pathway | PID_HNF3A_PATHWAY | 1.41e-03 | 44 | 18 | 2 | M285 | |
| Pathway | PID_AR_TF_PATHWAY | 2.04e-03 | 53 | 18 | 2 | M151 | |
| Pathway | REACTOME_ESR_MEDIATED_SIGNALING | 2.57e-03 | 220 | 18 | 3 | M27794 | |
| Pathway | REACTOME_ESTROGEN_DEPENDENT_GENE_EXPRESSION | 2.87e-03 | 63 | 18 | 2 | MM15613 | |
| Pathway | PID_ERA_GENOMIC_PATHWAY | 2.96e-03 | 64 | 18 | 2 | M200 | |
| Pathway | PID_HIF1_TFPATHWAY | 3.15e-03 | 66 | 18 | 2 | M255 | |
| Pubmed | 1.95e-08 | 10 | 20 | 3 | 31433982 | ||
| Pubmed | 1.10e-07 | 17 | 20 | 3 | 19183483 | ||
| Pubmed | 2.86e-07 | 23 | 20 | 3 | 19737349 | ||
| Pubmed | PAX7-FKHR fusion gene inhibits myogenic differentiation via NF-kappaB upregulation. | 3.14e-07 | 2 | 20 | 2 | 22374423 | |
| Pubmed | A novel SRC-2-dependent regulation of epithelial-mesenchymal transition in breast cancer cells. | 3.14e-07 | 2 | 20 | 2 | 30048685 | |
| Pubmed | FOXO1 stimulates ceruloplasmin promoter activity in human hepatoma cells treated with IL-6. | 3.14e-07 | 2 | 20 | 2 | 21185807 | |
| Pubmed | Homeostatic levels of SRC-2 and SRC-3 promote early human adipogenesis. | 3.14e-07 | 2 | 20 | 2 | 21220509 | |
| Pubmed | 3.14e-07 | 2 | 20 | 2 | 30273195 | ||
| Pubmed | 3.14e-07 | 2 | 20 | 2 | 26040939 | ||
| Pubmed | 9.42e-07 | 3 | 20 | 2 | 10871843 | ||
| Pubmed | 9.42e-07 | 3 | 20 | 2 | 21035760 | ||
| Pubmed | Divergent transcriptional and transforming properties of PAX3-FOXO1 and PAX7-FOXO1 paralogs. | 9.42e-07 | 3 | 20 | 2 | 35604932 | |
| Pubmed | 9.42e-07 | 3 | 20 | 2 | 18845648 | ||
| Pubmed | 9.42e-07 | 3 | 20 | 2 | 22089931 | ||
| Pubmed | The function of TIF2/GRIP1 in mouse reproduction is distinct from those of SRC-1 and p/CIP. | 9.42e-07 | 3 | 20 | 2 | 12138202 | |
| Pubmed | 9.42e-07 | 3 | 20 | 2 | 21059860 | ||
| Pubmed | 9.42e-07 | 3 | 20 | 2 | 22197543 | ||
| Pubmed | 9.42e-07 | 3 | 20 | 2 | 21735116 | ||
| Pubmed | [Alveolar rhabdomyosarcoma: Two fusion-negative cases lacking PAX3-FOXO1 and PAX7-FOXO1]. | 9.42e-07 | 3 | 20 | 2 | 34980443 | |
| Pubmed | Absence of the steroid receptor coactivator-3 induces B-cell lymphoma. | 9.42e-07 | 3 | 20 | 2 | 16675958 | |
| Pubmed | Pax7-FKHR transcriptional activity is enhanced by transcriptionally repressed MyoD. | 9.42e-07 | 3 | 20 | 2 | 21321994 | |
| Pubmed | 9.42e-07 | 3 | 20 | 2 | 26929406 | ||
| Pubmed | 9.42e-07 | 3 | 20 | 2 | 20351326 | ||
| Pubmed | 9.42e-07 | 3 | 20 | 2 | 11923473 | ||
| Pubmed | 9.42e-07 | 3 | 20 | 2 | 15698540 | ||
| Pubmed | 9.42e-07 | 3 | 20 | 2 | 9506940 | ||
| Pubmed | Structure and chromosomal locations of mouse steroid receptor coactivator gene family. | 9.42e-07 | 3 | 20 | 2 | 10501088 | |
| Pubmed | 9.42e-07 | 3 | 20 | 2 | 28390937 | ||
| Pubmed | 9.42e-07 | 3 | 20 | 2 | 15688409 | ||
| Pubmed | 9.42e-07 | 3 | 20 | 2 | 19277704 | ||
| Pubmed | Research resource: loss of the steroid receptor coactivators confers neurobehavioral consequences. | 9.42e-07 | 3 | 20 | 2 | 23927929 | |
| Pubmed | FoxO1 and FoxA1/2 form a complex on DNA and cooperate to open chromatin at insulin-regulated genes. | 9.42e-07 | 3 | 20 | 2 | 30142277 | |
| Pubmed | 9.42e-07 | 3 | 20 | 2 | 19052561 | ||
| Pubmed | Pax3-fkhr and pax7-fkhr fusion genes impact outcome of alveolar rhabdomyosarcoma in children. | 9.42e-07 | 3 | 20 | 2 | 17613043 | |
| Pubmed | [Expression of fusion gene PAX3/PAX7-FKHR and chromosomal aberration in rhabdomyosarcoma]. | 9.42e-07 | 3 | 20 | 2 | 17285543 | |
| Pubmed | 9.42e-07 | 3 | 20 | 2 | 12039929 | ||
| Pubmed | The genomic analysis of the impact of steroid receptor coactivators ablation on hepatic metabolism. | 9.42e-07 | 3 | 20 | 2 | 16423883 | |
| Pubmed | 1.88e-06 | 4 | 20 | 2 | 26066330 | ||
| Pubmed | 1.88e-06 | 4 | 20 | 2 | 18988640 | ||
| Pubmed | 1.88e-06 | 4 | 20 | 2 | 12893883 | ||
| Pubmed | 1.88e-06 | 4 | 20 | 2 | 19198856 | ||
| Pubmed | Ablation of steroid receptor coactivator-3 resembles the human CACT metabolic myopathy. | 1.88e-06 | 4 | 20 | 2 | 22560224 | |
| Pubmed | 1.88e-06 | 4 | 20 | 2 | 18267973 | ||
| Pubmed | Selective recruitment of p160 coactivators on glucocorticoid-regulated promoters in Schwann cells. | 1.88e-06 | 4 | 20 | 2 | 15331759 | |
| Pubmed | 1.88e-06 | 4 | 20 | 2 | 10598588 | ||
| Pubmed | 1.88e-06 | 4 | 20 | 2 | 11851396 | ||
| Pubmed | 1.88e-06 | 4 | 20 | 2 | 26267537 | ||
| Pubmed | ALK expression in rhabdomyosarcomas: correlation with histologic subtype and fusion status. | 1.88e-06 | 4 | 20 | 2 | 18788887 | |
| Pubmed | 1.88e-06 | 4 | 20 | 2 | 15184910 | ||
| Pubmed | 1.88e-06 | 4 | 20 | 2 | 19462000 | ||
| Pubmed | 1.88e-06 | 4 | 20 | 2 | 19095746 | ||
| Pubmed | 1.88e-06 | 4 | 20 | 2 | 15563469 | ||
| Pubmed | 1.88e-06 | 4 | 20 | 2 | 15563453 | ||
| Pubmed | 2.13e-06 | 709 | 20 | 6 | 22988430 | ||
| Pubmed | 3.14e-06 | 5 | 20 | 2 | 10652338 | ||
| Pubmed | Identification of COUP-TFII orphan nuclear receptor as a retinoic acid-activated receptor. | 3.14e-06 | 5 | 20 | 2 | 18798693 | |
| Pubmed | 3.14e-06 | 5 | 20 | 2 | 12554772 | ||
| Pubmed | 3.14e-06 | 5 | 20 | 2 | 17950690 | ||
| Pubmed | 3.14e-06 | 5 | 20 | 2 | 11353774 | ||
| Pubmed | 3.14e-06 | 5 | 20 | 2 | 17476305 | ||
| Pubmed | 3.14e-06 | 5 | 20 | 2 | 17854779 | ||
| Pubmed | Dual role of the arginine methyltransferase CARM1 in the regulation of c-Fos target genes. | 3.14e-06 | 5 | 20 | 2 | 18511550 | |
| Pubmed | 3.14e-06 | 5 | 20 | 2 | 14766010 | ||
| Pubmed | SRC-1 and GRIP1 coactivate transcription with hepatocyte nuclear factor 4. | 3.14e-06 | 5 | 20 | 2 | 9812974 | |
| Pubmed | 3.14e-06 | 5 | 20 | 2 | 10757795 | ||
| Pubmed | 3.14e-06 | 5 | 20 | 2 | 14966121 | ||
| Pubmed | 3.14e-06 | 5 | 20 | 2 | 12714702 | ||
| Pubmed | 3.14e-06 | 5 | 20 | 2 | 10381882 | ||
| Pubmed | 3.14e-06 | 5 | 20 | 2 | 10803578 | ||
| Pubmed | 3.14e-06 | 5 | 20 | 2 | 12514218 | ||
| Pubmed | Ligands specify coactivator nuclear receptor (NR) box affinity for estrogen receptor subtypes. | 3.14e-06 | 5 | 20 | 2 | 11376110 | |
| Pubmed | 4.71e-06 | 6 | 20 | 2 | 16373399 | ||
| Pubmed | 4.71e-06 | 6 | 20 | 2 | 12630920 | ||
| Pubmed | 4.71e-06 | 6 | 20 | 2 | 16728408 | ||
| Pubmed | 4.71e-06 | 6 | 20 | 2 | 16923966 | ||
| Pubmed | 6.59e-06 | 7 | 20 | 2 | 21195347 | ||
| Pubmed | BRCA1-IRIS regulates cyclin D1 expression in breast cancer cells. | 6.59e-06 | 7 | 20 | 2 | 16860316 | |
| Pubmed | Characterization of the physical interaction between estrogen receptor alpha and JUN proteins. | 6.59e-06 | 7 | 20 | 2 | 11477071 | |
| Pubmed | The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. | 6.59e-06 | 7 | 20 | 2 | 9192892 | |
| Pubmed | Temporal formation of distinct thyroid hormone receptor coactivator complexes in HeLa cells. | 6.59e-06 | 7 | 20 | 2 | 11117530 | |
| Pubmed | Sestrin prevents atrophy of disused and aging muscles by integrating anabolic and catabolic signals. | 6.59e-06 | 7 | 20 | 2 | 31929511 | |
| Pubmed | 6.59e-06 | 7 | 20 | 2 | 12709428 | ||
| Pubmed | TRIM33 drives prostate tumor growth by stabilizing androgen receptor from Skp2-mediated degradation. | 6.97e-06 | 220 | 20 | 4 | 35785414 | |
| Pubmed | An atlas of combinatorial transcriptional regulation in mouse and man. | 7.24e-06 | 877 | 20 | 6 | 20211142 | |
| Pubmed | 8.78e-06 | 8 | 20 | 2 | 12082103 | ||
| Pubmed | 8.78e-06 | 8 | 20 | 2 | 23178929 | ||
| Pubmed | 8.78e-06 | 8 | 20 | 2 | 11050077 | ||
| Pubmed | Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) Coactivator activity by I kappa B kinase. | 8.78e-06 | 8 | 20 | 2 | 11971985 | |
| Pubmed | 8.78e-06 | 8 | 20 | 2 | 15489287 | ||
| Pubmed | 8.78e-06 | 8 | 20 | 2 | 14747462 | ||
| Pubmed | 8.78e-06 | 8 | 20 | 2 | 10490106 | ||
| Pubmed | Targeting of SWI/SNF chromatin remodelling complexes to estrogen-responsive genes. | 8.78e-06 | 8 | 20 | 2 | 12145209 | |
| Pubmed | 9.43e-06 | 1429 | 20 | 7 | 35140242 | ||
| Pubmed | 1.13e-05 | 9 | 20 | 2 | 19176441 | ||
| Pubmed | 1.13e-05 | 9 | 20 | 2 | 11087842 | ||
| Pubmed | 1.13e-05 | 9 | 20 | 2 | 14966289 | ||
| Pubmed | 1.13e-05 | 9 | 20 | 2 | 15888456 | ||
| Pubmed | 1.13e-05 | 9 | 20 | 2 | 15184363 | ||
| Pubmed | 1.16e-05 | 77 | 20 | 3 | 21525287 | ||
| Pubmed | 1.20e-05 | 78 | 20 | 3 | 28611094 | ||
| Interaction | NFIA interactions | 9.27e-07 | 188 | 20 | 5 | int:NFIA | |
| Interaction | TLE3 interactions | 1.26e-06 | 376 | 20 | 6 | int:TLE3 | |
| Interaction | NCOA3 interactions | 2.20e-06 | 224 | 20 | 5 | int:NCOA3 | |
| Interaction | DLX5 interactions | 3.00e-06 | 29 | 20 | 3 | int:DLX5 | |
| Interaction | PAX7 interactions | 6.13e-06 | 124 | 20 | 4 | int:PAX7 | |
| Interaction | NR5A2 interactions | 8.70e-06 | 41 | 20 | 3 | int:NR5A2 | |
| Interaction | NFIB interactions | 1.05e-05 | 142 | 20 | 4 | int:NFIB | |
| Interaction | IGKV3-20 interactions | 2.61e-05 | 8 | 20 | 2 | int:IGKV3-20 | |
| Interaction | HNF1B interactions | 3.30e-05 | 190 | 20 | 4 | int:HNF1B | |
| Interaction | MYOD1 interactions | 3.57e-05 | 194 | 20 | 4 | int:MYOD1 | |
| Interaction | ETV4 interactions | 4.20e-05 | 69 | 20 | 3 | int:ETV4 | |
| Interaction | NFIC interactions | 4.87e-05 | 210 | 20 | 4 | int:NFIC | |
| Interaction | SOX7 interactions | 7.04e-05 | 82 | 20 | 3 | int:SOX7 | |
| Interaction | SOX10 interactions | 9.92e-05 | 92 | 20 | 3 | int:SOX10 | |
| Interaction | SOX17 interactions | 1.09e-04 | 95 | 20 | 3 | int:SOX17 | |
| Interaction | SMAD4 interactions | 1.38e-04 | 530 | 20 | 5 | int:SMAD4 | |
| Interaction | HNF4A interactions | 1.38e-04 | 275 | 20 | 4 | int:HNF4A | |
| Interaction | DLX1 interactions | 1.42e-04 | 18 | 20 | 2 | int:DLX1 | |
| Interaction | SMARCE1 interactions | 1.63e-04 | 287 | 20 | 4 | int:SMARCE1 | |
| Interaction | PAX8 interactions | 1.73e-04 | 111 | 20 | 3 | int:PAX8 | |
| Interaction | TBR1 interactions | 1.83e-04 | 113 | 20 | 3 | int:TBR1 | |
| Interaction | LDB1 interactions | 1.92e-04 | 115 | 20 | 3 | int:LDB1 | |
| Interaction | DLX2 interactions | 1.94e-04 | 21 | 20 | 2 | int:DLX2 | |
| Interaction | TBXT interactions | 1.97e-04 | 116 | 20 | 3 | int:TBXT | |
| Interaction | SATB1 interactions | 1.97e-04 | 116 | 20 | 3 | int:SATB1 | |
| Interaction | SP7 interactions | 2.03e-04 | 304 | 20 | 4 | int:SP7 | |
| Interaction | PPARG interactions | 2.11e-04 | 307 | 20 | 4 | int:PPARG | |
| Interaction | CREBBP interactions | 2.44e-04 | 599 | 20 | 5 | int:CREBBP | |
| Interaction | PAX9 interactions | 2.76e-04 | 130 | 20 | 3 | int:PAX9 | |
| Interaction | TLE6 interactions | 2.77e-04 | 25 | 20 | 2 | int:TLE6 | |
| Interaction | SOX15 interactions | 3.50e-04 | 141 | 20 | 3 | int:SOX15 | |
| Interaction | TRPS1 interactions | 3.65e-04 | 143 | 20 | 3 | int:TRPS1 | |
| Interaction | ETV1 interactions | 3.74e-04 | 29 | 20 | 2 | int:ETV1 | |
| Interaction | NCOA1 interactions | 3.88e-04 | 146 | 20 | 3 | int:NCOA1 | |
| Interaction | SATB2 interactions | 4.98e-04 | 159 | 20 | 3 | int:SATB2 | |
| Interaction | LHX4 interactions | 5.64e-04 | 166 | 20 | 3 | int:LHX4 | |
| Interaction | NRIP1 interactions | 6.05e-04 | 170 | 20 | 3 | int:NRIP1 | |
| Interaction | EGR2 interactions | 6.15e-04 | 171 | 20 | 3 | int:EGR2 | |
| Interaction | TLX1 interactions | 6.58e-04 | 175 | 20 | 3 | int:TLX1 | |
| Interaction | ARID1B interactions | 6.80e-04 | 177 | 20 | 3 | int:ARID1B | |
| Interaction | GAST interactions | 7.14e-04 | 40 | 20 | 2 | int:GAST | |
| Interaction | NKX2-1 interactions | 7.14e-04 | 180 | 20 | 3 | int:NKX2-1 | |
| Interaction | NUP35 interactions | 7.16e-04 | 424 | 20 | 4 | int:NUP35 | |
| Interaction | ALG13 interactions | 7.49e-04 | 183 | 20 | 3 | int:ALG13 | |
| Interaction | TFF1 interactions | 7.50e-04 | 41 | 20 | 2 | int:TFF1 | |
| Interaction | THRB interactions | 7.86e-04 | 186 | 20 | 3 | int:THRB | |
| Interaction | GATA3 interactions | 7.98e-04 | 187 | 20 | 3 | int:GATA3 | |
| Interaction | KLF5 interactions | 9.01e-04 | 195 | 20 | 3 | int:KLF5 | |
| Interaction | TRIM33 interactions | 9.17e-04 | 453 | 20 | 4 | int:TRIM33 | |
| Interaction | FEV interactions | 1.01e-03 | 203 | 20 | 3 | int:FEV | |
| Interaction | ALX4 interactions | 1.03e-03 | 48 | 20 | 2 | int:ALX4 | |
| Interaction | NR1I3 interactions | 1.03e-03 | 48 | 20 | 2 | int:NR1I3 | |
| Interaction | NR1I2 interactions | 1.03e-03 | 48 | 20 | 2 | int:NR1I2 | |
| Interaction | MEF2C interactions | 1.30e-03 | 54 | 20 | 2 | int:MEF2C | |
| Interaction | RARA interactions | 1.33e-03 | 223 | 20 | 3 | int:RARA | |
| Interaction | ERG interactions | 1.33e-03 | 223 | 20 | 3 | int:ERG | |
| Interaction | LDB2 interactions | 1.40e-03 | 56 | 20 | 2 | int:LDB2 | |
| Interaction | TPRX2 interactions | 1.40e-03 | 56 | 20 | 2 | int:TPRX2 | |
| Interaction | NFIX interactions | 1.40e-03 | 227 | 20 | 3 | int:NFIX | |
| Interaction | ZNF503 interactions | 1.45e-03 | 57 | 20 | 2 | int:ZNF503 | |
| Interaction | NR2F1 interactions | 1.50e-03 | 58 | 20 | 2 | int:NR2F1 | |
| Interaction | SSBP4 interactions | 1.55e-03 | 59 | 20 | 2 | int:SSBP4 | |
| Interaction | FLI1 interactions | 1.71e-03 | 62 | 20 | 2 | int:FLI1 | |
| Interaction | TMEM216 interactions | 1.76e-03 | 246 | 20 | 3 | int:TMEM216 | |
| Interaction | CRX interactions | 1.92e-03 | 254 | 20 | 3 | int:CRX | |
| Interaction | ARNT interactions | 1.95e-03 | 255 | 20 | 3 | int:ARNT | |
| Interaction | ESRRA interactions | 1.99e-03 | 67 | 20 | 2 | int:ESRRA | |
| Interaction | HBA1 interactions | 1.99e-03 | 67 | 20 | 2 | int:HBA1 | |
| Interaction | SOX2 interactions | 2.00e-03 | 1422 | 20 | 6 | int:SOX2 | |
| Interaction | DCTN6 interactions | 2.05e-03 | 68 | 20 | 2 | int:DCTN6 | |
| Interaction | GCM1 interactions | 2.05e-03 | 68 | 20 | 2 | int:GCM1 | |
| Interaction | NR1H2 interactions | 2.05e-03 | 68 | 20 | 2 | int:NR1H2 | |
| GeneFamily | Zinc fingers ZZ-type|Lysine acetyltransferases | 9.91e-05 | 17 | 16 | 2 | 486 | |
| GeneFamily | Ataxins|Trinucleotide repeat containing | 2.18e-04 | 25 | 16 | 2 | 775 | |
| GeneFamily | Forkhead boxes | 6.49e-04 | 43 | 16 | 2 | 508 | |
| GeneFamily | Basic helix-loop-helix proteins | 4.16e-03 | 110 | 16 | 2 | 420 | |
| Coexpression | ZHOU_PANCREATIC_BETA_CELL | 3.03e-05 | 11 | 20 | 2 | MM1247 | |
| Coexpression | ZHOU_PANCREATIC_BETA_CELL | 3.03e-05 | 11 | 20 | 2 | M1863 | |
| Coexpression | GAUTAM_EYE_IRIS_CILIARY_BODY_COL9A1_HIGH_CILIARY_BODY_CELLS | 6.04e-05 | 101 | 20 | 3 | M43627 | |
| Coexpression | LAKE_ADULT_KIDNEY_C21_COLLECTING_DUCT_INTERCALATED_CELLS_TYPE_B | 6.40e-05 | 103 | 20 | 3 | M39240 | |
| Coexpression | LAKE_ADULT_KIDNEY_C16_COLLECTING_SYSTEM_PRINCIPAL_CELLS_CORTEX | 1.62e-04 | 141 | 20 | 3 | M39235 | |
| Coexpression | LAKE_ADULT_KIDNEY_C20_COLLECTING_DUCT_INTERCALATED_CELLS_TYPE_A_CORTEX | 2.03e-04 | 152 | 20 | 3 | M39239 | |
| Coexpression | LAKE_ADULT_KIDNEY_C27_VASCULAR_SMOOTH_MUSCLE_CELLS_AND_PERICYTES | 2.15e-04 | 155 | 20 | 3 | M39246 | |
| Coexpression | MCBRYAN_PUBERTAL_TGFB1_TARGETS_UP | 2.72e-04 | 168 | 20 | 3 | M1124 | |
| Coexpression | GSE3565_CTRL_VS_LPS_INJECTED_SPLENOCYTES_DN | 3.07e-04 | 175 | 20 | 3 | M6328 | |
| Coexpression | BENPORATH_NOS_TARGETS | 3.28e-04 | 179 | 20 | 3 | M14573 | |
| Coexpression | MCBRYAN_PUBERTAL_TGFB1_TARGETS_UP | 3.44e-04 | 182 | 20 | 3 | MM993 | |
| Coexpression | GSE34156_NOD2_LIGAND_VS_NOD2_AND_TLR1_TLR2_LIGAND_24H_TREATED_MONOCYTE_UP | 3.96e-04 | 191 | 20 | 3 | M8679 | |
| Coexpression | GU_PDEF_TARGETS_DN | 4.24e-04 | 40 | 20 | 2 | M10480 | |
| Coexpression | GSE23321_EFFECTOR_MEMORY_VS_NAIVE_CD8_TCELL_UP | 4.27e-04 | 196 | 20 | 3 | M8428 | |
| Coexpression | GSE22025_PROGESTERONE_VS_TGFB1_AND_PROGESTERONE_TREATED_CD4_TCELL_UP | 4.47e-04 | 199 | 20 | 3 | M8381 | |
| Coexpression | GSE21379_WT_VS_SAP_KO_CD4_TCELL_DN | 4.47e-04 | 199 | 20 | 3 | M7511 | |
| Coexpression | GSE19923_HEB_KO_VS_HEB_AND_E2A_KO_DP_THYMOCYTE_DN | 4.53e-04 | 200 | 20 | 3 | M7271 | |
| Coexpression | GSE17301_ACD3_ACD28_VS_ACD3_ACD28_AND_IFNA2_STIM_CD8_TCELL_DN | 4.53e-04 | 200 | 20 | 3 | M8040 | |
| Coexpression | GSE10273_HIGH_IL7_VS_HIGH_IL7_AND_IRF4_IN_IRF4_8_NULL_PRE_BCELL_DN | 4.53e-04 | 200 | 20 | 3 | M317 | |
| Coexpression | GSE15330_HSC_VS_LYMPHOID_PRIMED_MULTIPOTENT_PROGENITOR_UP | 4.53e-04 | 200 | 20 | 3 | M7018 | |
| Coexpression | GSE21063_CTRL_VS_ANTI_IGM_STIM_BCELL_16H_DN | 4.53e-04 | 200 | 20 | 3 | M8267 | |
| Coexpression | GSE27092_WT_VS_HDAC7_PHOSPHO_DEFICIENT_CD8_TCELL_UP | 4.53e-04 | 200 | 20 | 3 | M8203 | |
| Coexpression | GSE13522_WT_VS_IFNAR_KO_SKING_T_CRUZI_Y_STRAIN_INF_UP | 4.53e-04 | 200 | 20 | 3 | M2933 | |
| Coexpression | GSE2770_UNTREATED_VS_IL12_TREATED_ACT_CD4_TCELL_48H_UP | 4.53e-04 | 200 | 20 | 3 | M6044 | |
| Coexpression | GSE7460_CTRL_VS_TGFB_TREATED_ACT_CD8_TCELL_DN | 4.53e-04 | 200 | 20 | 3 | M5679 | |
| Coexpression | GSE16451_CTRL_VS_WEST_EQUINE_ENC_VIRUS_MATURE_NEURON_CELL_LINE_DN | 4.53e-04 | 200 | 20 | 3 | M7426 | |
| Coexpression | GSE360_L_MAJOR_VS_B_MALAYI_HIGH_DOSE_MAC_UP | 4.53e-04 | 200 | 20 | 3 | M5247 | |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_e14.5_ Genital tubercle M_emap-6706_k-means-cluster#5_top-relative-expression-ranked_500 | 3.83e-06 | 33 | 20 | 3 | gudmap_developingLowerUrinaryTract_e14.5_ Genital tubercle M_500_k5 | |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_e14.5_ Genital tubercle M_emap-6706_top-relative-expression-ranked_1000 | 7.07e-06 | 836 | 20 | 7 | gudmap_developingLowerUrinaryTract_e14.5_ Genital tubercle M_1000 | |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_P1_bladder_J_emap-30374_k-means-cluster#5_top-relative-expression-ranked_1000 | 1.40e-05 | 161 | 20 | 4 | gudmap_developingLowerUrinaryTract_P1_bladder_J_1000_k5 | |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_e14.5_ Genital tubercle M_emap-6706_k-means-cluster#4_top-relative-expression-ranked_1000 | 2.13e-05 | 58 | 20 | 3 | gudmap_developingLowerUrinaryTract_e14.5_ Genital tubercle M_1000_k4 | |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_e14.5_ Genital tubercle M_emap-6706_top-relative-expression-ranked_500 | 3.97e-05 | 429 | 20 | 5 | gudmap_developingLowerUrinaryTract_e14.5_ Genital tubercle M_500 | |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_e14.5_ Genital tubercle F_emap-6706_k-means-cluster#2_top-relative-expression-ranked_1000 | 4.26e-05 | 73 | 20 | 3 | gudmap_developingLowerUrinaryTract_e14.5_ Genital tubercle F_1000_k2 | |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_adult_ureter_emap-29479_top-relative-expression-ranked_100 | 5.20e-05 | 78 | 20 | 3 | gudmap_developingLowerUrinaryTract_adult_ureter_100 | |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_e14.5_ Genital tubercle_emap-6706_top-relative-expression-ranked_1000 | 5.55e-05 | 769 | 20 | 6 | gudmap_developingLowerUrinaryTract_e14.5_ Genital tubercle_1000 | |
| CoexpressionAtlas | FacebaseRNAseq_e9.5_Maxillary Arch_top-relative-expression-ranked_1000_k-means-cluster#4 | 5.86e-05 | 232 | 20 | 4 | Facebase_RNAseq_e9.5_Maxillary Arch_1000_K4 | |
| CoexpressionAtlas | kidney_adult_Mesangium_Meis_top-relative-expression-ranked_1000 | 1.11e-04 | 872 | 20 | 6 | gudmap_kidney_adult_Mesangium_Meis_1000 | |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_P1_ureter_emap-30363_k-means-cluster#1_top-relative-expression-ranked_100 | 1.43e-04 | 19 | 20 | 2 | gudmap_developingLowerUrinaryTract_P1_ureter_100_k1 | |
| CoexpressionAtlas | alpha beta T cells, T.4FP3+25+.Sp, 4+ 8- GFP+ 25+, Spleen, avg-3 | 2.67e-04 | 344 | 20 | 4 | GSM399365_500 | |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_adult_ureter_emap-29479_top-relative-expression-ranked_200 | 3.54e-04 | 149 | 20 | 3 | gudmap_developingLowerUrinaryTract_adult_ureter_200 | |
| CoexpressionAtlas | facebase_RNAseq_e14.5_palate_poster_proximal_ERK2_WT_2500_K1 | 3.61e-04 | 150 | 20 | 3 | facebase_RNAseq_e14.5_palate_poster_proximal_ERK2_WT_2500_K1 | |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_P1_ureter_emap-30363_k-means-cluster#2_top-relative-expression-ranked_200 | 3.61e-04 | 30 | 20 | 2 | gudmap_developingLowerUrinaryTract_P1_ureter_200_k2 | |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_e14.5_ urethra_emap-30902_k-means-cluster#3_top-relative-expression-ranked_200 | 4.37e-04 | 33 | 20 | 2 | DevelopingLowerUrinaryTract_e14.5_ urethra_emap-30902_k3_200 | |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_adult_ureter_emap-29479_top-relative-expression-ranked_1000 | 4.96e-04 | 736 | 20 | 5 | gudmap_developingLowerUrinaryTract_adult_ureter_1000 | |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_e14.5_ urethra_emap-30902_top-relative-expression-ranked_500 | 5.10e-04 | 408 | 20 | 4 | DevelopingLowerUrinaryTract_e14.5_ urethra_emap-30902_500 | |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_e14.5_ Genital tubercle F_emap-6706_top-relative-expression-ranked_200 | 5.11e-04 | 169 | 20 | 3 | gudmap_developingLowerUrinaryTract_e14.5_ Genital tubercle F_200 | |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_e14.5_ Genital tubercle M_emap-6706_top-relative-expression-ranked_200 | 5.66e-04 | 175 | 20 | 3 | gudmap_developingLowerUrinaryTract_e14.5_ Genital tubercle M_200 | |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_e14.5_ Genital tubercle F_emap-6706_top-relative-expression-ranked_500 | 6.10e-04 | 428 | 20 | 4 | gudmap_developingLowerUrinaryTract_e14.5_ Genital tubercle F_500 | |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_e14.5_ urethra_emap-30892_k-means-cluster#4_top-relative-expression-ranked_200 | 6.12e-04 | 39 | 20 | 2 | gudmap_developingLowerUrinaryTract_e14.5_ urethra_200_k4 | |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_e14.5_ urethra_emap-30892_top-relative-expression-ranked_1000 | 7.50e-04 | 806 | 20 | 5 | gudmap_developingLowerUrinaryTract_e14.5_ urethra_1000 | |
| CoexpressionAtlas | MESO-30 amniotic fluid MSC_vs_MESO-30 blastocyst-Confounder_removed-fold2.0_adjp0.05 | 7.63e-04 | 1245 | 20 | 6 | PCBC_ratio_MESO-30 amniotic fluid MSC_vs_MESO-30 blastocyst_cfr-2X-p05 | |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_e14.5_ bladder_emap-30872_k-means-cluster#4_top-relative-expression-ranked_500 | 7.79e-04 | 44 | 20 | 2 | gudmap_developingLowerUrinaryTract_e14.5_ bladder_500_k4 | |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_e14.5_ Genital tubercle F_emap-6706_top-relative-expression-ranked_1000 | 9.53e-04 | 850 | 20 | 5 | gudmap_developingLowerUrinaryTract_e14.5_ Genital tubercle F_1000 | |
| CoexpressionAtlas | kidney_adult_RenMedVasc_Tie2_top-relative-expression-ranked_1000 | 9.53e-04 | 850 | 20 | 5 | gudmap_kidney_adult_RenMedVasc_Tie2_1000 | |
| CoexpressionAtlas | FacebaseRNAseq_e9.5_Maxillary Arch_top-relative-expression-ranked_500 | 9.59e-04 | 483 | 20 | 4 | Facebase_RNAseq_e9.5_Maxillary Arch_500 | |
| CoexpressionAtlas | CD positive, CD4 Control, 4+ 8- B220-, Spleen, avg-4 | 9.60e-04 | 210 | 20 | 3 | GSM403995_500 | |
| CoexpressionAtlas | kidney_adult_GlomCapSys_Tie2_top-relative-expression-ranked_1000 | 9.63e-04 | 852 | 20 | 5 | gudmap_kidney_adult_GlomCapSys_Tie2_1000 | |
| ToppCell | Parenchymal-NucSeq|Parenchymal / Cell types per location group and 10X technology with lineage, and cell group designations | 2.31e-08 | 198 | 20 | 5 | 1996373bdccc55aac347d349bd22f6aad6d0c668 | |
| ToppCell | LPS-IL1RA+antiTNF-Epithelial_alveolar-AT_2-Differentiating_AT2|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.30e-06 | 186 | 20 | 4 | e83718fabb057100835d3357df407f283d23fe16 | |
| ToppCell | LPS-IL1RA-Epithelial_alveolar-AT_2-Differentiating_AT2|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.36e-06 | 188 | 20 | 4 | 4bdf8d49af0e9da349b16e3f012e1b0eec04cc4f | |
| ToppCell | nucseq|World / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 1.51e-06 | 193 | 20 | 4 | 779276e775cb2492e8dd36436295a536084a6415 | |
| ToppCell | renal_papilla_nuclei-Hypertensive_with+without-CKD|renal_papilla_nuclei / Celltypes from Cells and Nuclei per compartment and clinical group | 1.51e-06 | 193 | 20 | 4 | ca7c0a4ceb05bced90f6cdc53d278e547fb241e9 | |
| ToppCell | Bronchial-NucSeq|Bronchial / Cell types per location group and 10X technology with lineage, and cell group designations | 1.60e-06 | 196 | 20 | 4 | ab53c742866945545a92e2e61850d63c80d9a2a6 | |
| ToppCell | 5'-Airway_Nasal-Epithelial-Epithelial_transtional-secretory-club_cell|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 1.70e-06 | 199 | 20 | 4 | 6977f939ddbc47d4921f36c0a61a205259fe1284 | |
| ToppCell | 5'-Airway_Nasal-Epithelial-Epithelial_transtional-secretory-club_cell-Club_(nasal)|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 1.70e-06 | 199 | 20 | 4 | fbd39d34636137d1b877dd8815d58f124990136b | |
| ToppCell | LPS_IL1RA_TNF-Endothelial-Endothelial-Vein|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type | 1.74e-06 | 200 | 20 | 4 | 7eb366b2c5394af7c77650bde6261e7dac67154e | |
| ToppCell | 5'-Airway_Nasal-Epithelial-Epithelial_transtional-secretory-club_cell-Club_(nasal)-Club_(nasal)_L.0.2.1.0|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 1.74e-06 | 200 | 20 | 4 | 8c4c396e99be6131a8fa60d86214d561031b12bf | |
| ToppCell | Neuronal-Inhibitory-iA-iA_1(SST_PAX6)|Neuronal / cells hierarchy compared to all cells using T-Statistic | 1.74e-06 | 200 | 20 | 4 | d0167f96314be78b6d867bbcc6e4396071d931b8 | |
| ToppCell | Neuronal-Inhibitory-iA-iA_1(SST_PAX6)-PAX6|Neuronal / cells hierarchy compared to all cells using T-Statistic | 1.74e-06 | 200 | 20 | 4 | 8a8f9d9e5ffab3f736c4bd0a5bb616d442d137d1 | |
| ToppCell | LPS-IL1RA+antiTNF-Epithelial_alveolar-AT_1-Differentiating_AT2|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.77e-05 | 133 | 20 | 3 | 5bf5e654653e2c340891f51e3f2a30441b7b6b2b | |
| ToppCell | frontal_cortex-Neuronal-glutamatergic_neuron-L5_IT-L5_IT_ALM_Cpa6_Gpr88|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype | 3.37e-05 | 142 | 20 | 3 | 84742a7e35bab09ee1cca80cfe120b613d6aed6a | |
| ToppCell | Adult-Epithelial-basal_cell-D122|Adult / Lineage, Cell type, age group and donor | 4.30e-05 | 154 | 20 | 3 | 38d346402417960044ae999e61f0092b46f2b591 | |
| ToppCell | droplet-Kidney-KIDNEY-30m-Lymphocytic-nan|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.56e-05 | 168 | 20 | 3 | 1fabb2455ce15315f19f01ea9308bc9e453cc095 | |
| ToppCell | COVID-19-Heart-Neuronal|Heart / Disease (COVID-19 only), tissue and cell type | 6.07e-05 | 173 | 20 | 3 | 6fb5f9e6536a5d57fd8e6657b494047a2d0bc9c7 | |
| ToppCell | LPS-antiTNF-Lymphocytic_NKT-iNKT/MAIT|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 6.17e-05 | 174 | 20 | 3 | 61aa89b56ebda0eba1ba675d5f036992967f670f | |
| ToppCell | Basal_cells-Cryobiopsy_01|World / lung cells shred on cell class, cell subclass, sample id | 6.17e-05 | 174 | 20 | 3 | a0060be3940043015dcc49a5157de5541aed24a1 | |
| ToppCell | LPS-antiTNF-Lymphocytic_NKT-iNKT/MAIT-iNKT-MAIT|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 6.28e-05 | 175 | 20 | 3 | 98cb577df466700e72d1bbc6689205ccf2e7fcba | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_PAX6-Inh_L1_PAX6_GRIP2|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 6.28e-05 | 175 | 20 | 3 | 0c648e7f67ffbe3b476a2ca77d246554f8cd1882 | |
| ToppCell | Fetal_29-31_weeks-Epithelial-club_cell-D088|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 6.39e-05 | 176 | 20 | 3 | 3bbac5c2397535631fce8fa98f6ddb4fe0260351 | |
| ToppCell | droplet-Large_Intestine-COLON_PROXIMAL-30m-Hematologic|Large_Intestine / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.61e-05 | 178 | 20 | 3 | 0f5cf34609df791c8baebfdc6590f6eb4dbe0509 | |
| ToppCell | droplet-Large_Intestine-COLON_PROXIMAL-30m-Hematologic-hematopoietic_stem_cell|Large_Intestine / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.61e-05 | 178 | 20 | 3 | d9eba884e18a0c89bdc70c194bfe4d62cca164fa | |
| ToppCell | droplet-Large_Intestine-COLON_PROXIMAL-30m-Hematologic-hematopoietic_stem_cell|Large_Intestine / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.61e-05 | 178 | 20 | 3 | b03aa1de9d20895ebad55f6fcd6fe7a49335db5a | |
| ToppCell | LPS_only-Lymphocytic_NKT-iNKT/MAIT|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 6.72e-05 | 179 | 20 | 3 | de3ddc1264e43727be50d69b81cc84a3c91812a2 | |
| ToppCell | LPS_only-Lymphocytic_NKT-iNKT/MAIT-iNKT-MAIT|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 6.72e-05 | 179 | 20 | 3 | def981e97e3ff9019910c9af3861ca0d08eb0d0f | |
| ToppCell | COPD-Lymphoid-T_Regulatory|World / Disease state, Lineage and Cell class | 6.83e-05 | 180 | 20 | 3 | 51a12fbad5fa7bb12e6d616a02ff9b5141e2b063 | |
| ToppCell | RA-16._Neuronal|RA / Chamber and Cluster_Paper | 6.83e-05 | 180 | 20 | 3 | 5842febfdabac61ce970254fb0ef17a628f1b8c0 | |
| ToppCell | droplet-Liver-Npc-21m-Endothelial|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.06e-05 | 182 | 20 | 3 | dc55de945c6f78f32eb3a1b3520835eb8417e068 | |
| ToppCell | droplet-Liver-Npc-21m-Endothelial-endothelial_cell_of_hepatic_sinusoid|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.06e-05 | 182 | 20 | 3 | 010a7364da46101cb5068891fd7bc712ea8f13bd | |
| ToppCell | droplet-Liver-Npc-21m-Endothelial-endothelial_cell_of_hepatic_sinusoid|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.06e-05 | 182 | 20 | 3 | b1ec2015aad1181eac1bbf8d48ad6f2f7ed24a01 | |
| ToppCell | NS-critical-d_0-4-Lymphoid-Treg|d_0-4 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 7.17e-05 | 183 | 20 | 3 | f478dfa231fc1b12ead0183cc9d22077cdf43d1f | |
| ToppCell | Control-Epithelial_cells-Airway_goblet|Control / group, cell type (main and fine annotations) | 7.29e-05 | 184 | 20 | 3 | d92a71441e4e19f8c301999d8186f8e48e3cd162 | |
| ToppCell | Anterior_Cingulate_gyrus_(CgG)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_1-Inh_L1_ADARB2_ADAM33|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 7.41e-05 | 185 | 20 | 3 | 487fa382232564f075960899d50afa0edae5d258 | |
| ToppCell | facs-Thymus-Epithelium-24m-Mesenchymal-fibroblast|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.41e-05 | 185 | 20 | 3 | eaa54b76743628c89b4310be57b87fa92b75fd37 | |
| ToppCell | facs-Thymus-Epithelium-24m-Mesenchymal-fibroblast|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.41e-05 | 185 | 20 | 3 | f7f4c921d248c637351e2e882589b99ba7f04b66 | |
| ToppCell | facs-Thymus-Epithelium-24m-Mesenchymal|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.41e-05 | 185 | 20 | 3 | ff38a15af3dec36d9993f06623591872b5d1da9a | |
| ToppCell | COVID-19-Epithelial_cells-Airway_club|COVID-19 / group, cell type (main and fine annotations) | 7.41e-05 | 185 | 20 | 3 | cfe6fd73d817e173fe803bc1683c291d9bcb8608 | |
| ToppCell | COPD-Lymphoid-T_Regulatory|COPD / Disease state, Lineage and Cell class | 7.41e-05 | 185 | 20 | 3 | 846403edd4c8f646201d519055198fc38b7ffff9 | |
| ToppCell | Fetal_29-31_weeks-Epithelial-alveolar_epithelial_cell_type_2/Club-like_(AT2/Club-like)|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 7.53e-05 | 186 | 20 | 3 | 2ea5ff14861e5f91d0e6a5767c403a24045d715c | |
| ToppCell | 343B-Lymphocytic-CD4_T-cell-Treg_cell_4|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells) | 7.53e-05 | 186 | 20 | 3 | bca5215d406f1785bf3a420201d5686071fcaca5 | |
| ToppCell | pdx|World / Sample and Cell Type and Tumor Cluster (all cells) | 7.53e-05 | 186 | 20 | 3 | de8e538c8767d41b8a52f5e58ba1affd4e7244c4 | |
| ToppCell | pdx-Tumor_cells|World / Sample and Cell Type and Tumor Cluster (all cells) | 7.53e-05 | 186 | 20 | 3 | 0b88a87158a9ca8de3bf40a4ff1687150707a5f0 | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_PAX6|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 7.65e-05 | 187 | 20 | 3 | d2ffb2f34f07b0dd5d3cb3ee0275f46ebecf4146 | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_1-Inh_L1_ADARB2_ADAM33|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 7.65e-05 | 187 | 20 | 3 | 02105c82a9ba79d2f19e002188377fc3440770c2 | |
| ToppCell | COVID-19-kidney-Fibroblast-1|COVID-19 / Disease (COVID-19 only), tissue and cell type | 7.65e-05 | 187 | 20 | 3 | 76bfe8c42430a230a8bdf299575c444fb7780f24 | |
| ToppCell | Adult-Epithelial-alveolar_epithelial_cell_type_2-D175|Adult / Lineage, Cell type, age group and donor | 7.77e-05 | 188 | 20 | 3 | ec38def1fdbb34ed9b30244806975bd5a4370164 | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_PAX6-Inh_L1_PAX6_CA4|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 7.77e-05 | 188 | 20 | 3 | ee572246e0c2f41bdbc29a03edc67b831af95c09 | |
| ToppCell | Anterior_Cingulate_gyrus_(CgG)-Neuronal-Inh_GABAergic-i_Gaba_1-GABA_L1_LAMP5-Inh_L1-6_LAMP5_CA13_(Lamp5_Lhx6_1)|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 7.77e-05 | 188 | 20 | 3 | 3139540a656c0436b2123ea50741ff8d00112165 | |
| ToppCell | COVID-19-lung-Secretory|lung / Disease (COVID-19 only), tissue and cell type | 7.89e-05 | 189 | 20 | 3 | 84d48e3ed25bebb8bb8074b3a2c5e2e88cff7f25 | |
| ToppCell | Primary_Motor_Cortex_(M1)-Neuronal-Inh_GABAergic-i_Gaba_1-GABA_L1_LAMP5-Inh_L1-6_LAMP5_CA13_(Lamp5_Lhx6_1)|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 8.02e-05 | 190 | 20 | 3 | 2f54da2bee411f8868348a4c37034184b8f58a89 | |
| ToppCell | 3'-Airway_Nasal-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell-Goblet_(nasal)-Goblet_(nasal)_L.0.2.0.2|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 8.02e-05 | 190 | 20 | 3 | 6ea9fa08bd97bedcb21d3654467e7f8dd74c8fd0 | |
| ToppCell | COPD-Lymphoid-T_Regulatory|Lymphoid / Disease state, Lineage and Cell class | 8.14e-05 | 191 | 20 | 3 | 3ae18bc4e3dff49b5d5958da8ebc3f747274b69c | |
| ToppCell | facs-Marrow-B-cells-3m-Lymphocytic-precursor_B_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.14e-05 | 191 | 20 | 3 | 4aa29337f4d2528577bb90dc4abfb6eab93e120f | |
| ToppCell | COVID-19-lung-AT2|lung / Disease (COVID-19 only), tissue and cell type | 8.14e-05 | 191 | 20 | 3 | 276455a64c2c3503d5048615762eb2ee37f0ac70 | |
| ToppCell | facs-Marrow-B-cells-3m-Lymphocytic-pre_B_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.14e-05 | 191 | 20 | 3 | 318323a12029a7992f16382cb0c186f5b2e1ca47 | |
| ToppCell | COVID-19-Heart-EC_(POSTN)|Heart / Disease (COVID-19 only), tissue and cell type | 8.27e-05 | 192 | 20 | 3 | c0c34785a7bdf461722029b322e9184e3d9b3c26 | |
| ToppCell | Children_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_2-D139|Children_(3_yrs) / Lineage, Cell type, age group and donor | 8.27e-05 | 192 | 20 | 3 | cc9911e182a289779a2612bc213daae5607689e7 | |
| ToppCell | COVID-19-lung-Secretory|COVID-19 / Disease (COVID-19 only), tissue and cell type | 8.27e-05 | 192 | 20 | 3 | 59261098ccb52306f837f632ebaea45b90ad30fe | |
| ToppCell | Fetal_29-31_weeks-Epithelial-alveolar_epithelial_cell_type_2|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 8.27e-05 | 192 | 20 | 3 | fb2f0e897228f808d9ff734ad05e9b49dc38fa50 | |
| ToppCell | NS-critical-d_07-13-Epithelial-Secretory|d_07-13 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 8.53e-05 | 194 | 20 | 3 | 2172d951896265243d14996eacce5aab5e14e26e | |
| ToppCell | 3'-Airway_Nasal-Epithelial-Epithelial_transtional-secretory-club_cell-Club_(nasal)-Club_(nasal)_L.0.2.1.0|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 8.66e-05 | 195 | 20 | 3 | b9a1c5836eb0ca92df788c3ee093b0d9ec7b8ad9 | |
| ToppCell | NS-critical-LOC-Epithelial-Secretory|LOC / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 8.66e-05 | 195 | 20 | 3 | b0d782eeee30c797b4da9b3be29b864983fd9e71 | |
| ToppCell | RA-02._Fibroblast_II|RA / Chamber and Cluster_Paper | 8.66e-05 | 195 | 20 | 3 | 6a02ebbeb3199447ddce64d92d8809436e040eba | |
| ToppCell | nucseq-Epithelial|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 8.66e-05 | 195 | 20 | 3 | 9406866f99555198a9be311fbd65751b70f35446 | |
| ToppCell | NS-moderate-d_16-33-Epithelial-Secretory|d_16-33 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 8.79e-05 | 196 | 20 | 3 | 70384c1da9baed843f414cfd1403ddd586a2db07 | |
| ToppCell | critical-Epithelial-Secretory|critical / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls | 8.79e-05 | 196 | 20 | 3 | 7da687eb983a54c28ee990424cc52e01caf5f4aa | |
| ToppCell | NS-moderate-d_07-13-Epithelial-Secretory|d_07-13 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 8.79e-05 | 196 | 20 | 3 | 47930de6b47b7bf22d8dae8b7419a9cd1d22f0ea | |
| ToppCell | MS-CD4-exh_CD4|MS / Condition, Cell_class and T cell subcluster | 8.79e-05 | 196 | 20 | 3 | d0217eccaa2cbf4ce9934e9d2e0c34a7f5c1a57e | |
| ToppCell | Tracheal-10x3prime_v2-Stromal-Fibroblastic-Fibro_immune_recruiting|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations | 8.92e-05 | 197 | 20 | 3 | 4edf043e8f586fd375f56485841fe992a18bf853 | |
| ToppCell | AT2_cells-IPF_03|World / lung cells shred on cell class, cell subclass, sample id | 8.92e-05 | 197 | 20 | 3 | 5e0d222872a25bb9e9069d3dffda2844bb69874a | |
| ToppCell | distal-Epithelial-Club-2|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 9.06e-05 | 198 | 20 | 3 | 77c7fa7626ea35cb50de9c2f2df637d22e77d3fe | |
| ToppCell | distal-2-Epithelial-Club|2 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 9.06e-05 | 198 | 20 | 3 | 3055c03896fbfac82a3072e51c0c54d68131cf1a | |
| ToppCell | NS-critical-LOC-Epithelial-Secretory_LYPD2|LOC / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 9.06e-05 | 198 | 20 | 3 | 4a481e1edb80b950c823ed926842cd5132cfb27f | |
| ToppCell | medial-Epithelial-Club|medial / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 9.06e-05 | 198 | 20 | 3 | a861cf5bb1950ed5f0363b8a834a1c246e151389 | |
| ToppCell | Parenchymal-10x5prime-Epithelial-Epi_airway_secretory-Secretory_Club|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 9.06e-05 | 198 | 20 | 3 | 5d57acbe0d245f8bd217eeea07af060092898fbd | |
| ToppCell | medial-2-Epithelial-Club|2 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 9.06e-05 | 198 | 20 | 3 | 7f59d949190c10af13cbd13f81a795483deb9d14 | |
| ToppCell | medial-Epithelial-Club-2|medial / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 9.06e-05 | 198 | 20 | 3 | da7881351a71cde926325ab3e22d772f64cfab80 | |
| ToppCell | PSB-critical-LOC-Epithelial|LOC / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 9.19e-05 | 199 | 20 | 3 | 58dcb0eedafa8629585dc99e53147e2287f49689 | |
| ToppCell | cellseq2-Epithelial|cellseq2 / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 9.19e-05 | 199 | 20 | 3 | 2d4fb558845764f937efaf39962caaeb2c85478b | |
| ToppCell | NS-control-d_0-4-Epithelial-Secretory|d_0-4 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 9.19e-05 | 199 | 20 | 3 | 32bdfff40fd442b88489c8b0f79af3927a51a03c | |
| ToppCell | NS-critical-d_07-13-Epithelial|d_07-13 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 9.19e-05 | 199 | 20 | 3 | b88a81cd2a89f4d27100c96ae4324dcee68daf83 | |
| ToppCell | Parenchymal-NucSeq-Epithelial-Epi_alveolar|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 9.19e-05 | 199 | 20 | 3 | 8587bd98de7767a575088afbea07a1feb4516b9b | |
| ToppCell | Tracheal-NucSeq|Tracheal / Cell types per location group and 10X technology with lineage, and cell group designations | 9.19e-05 | 199 | 20 | 3 | 94b94b17ca18b8dc27b91da1f2ccf89e03cc7035 | |
| ToppCell | critical-Epithelial|critical / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls | 9.19e-05 | 199 | 20 | 3 | bbb44e2a52f102a6d891ead6c06d6c07221abd33 | |
| ToppCell | Parenchymal-NucSeq-Epithelial|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 9.19e-05 | 199 | 20 | 3 | 5cea0d9e261903e0eaad60c28a07dff72ce65027 | |
| ToppCell | NS-critical-d_16-33-Epithelial|d_16-33 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 9.19e-05 | 199 | 20 | 3 | 3b68197ec01c5f2b315d9e9b6eb02d5f6b5b77a3 | |
| ToppCell | cellseq2-Epithelial-Epithelial_Glandular|cellseq2 / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 9.19e-05 | 199 | 20 | 3 | ca78fd6e310232b25b864ed02ff9242fe1aa8206 | |
| ToppCell | control-Epithelial-Secretory|Epithelial / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls | 9.19e-05 | 199 | 20 | 3 | 3d01f90ffd271ca00129192787e4921bdca7e01e | |
| ToppCell | control-Epithelial-Secretory|control / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls | 9.19e-05 | 199 | 20 | 3 | 262e5b8a52c8ddb0b47048c786e8bdb7158e1b9a | |
| ToppCell | NS-critical-LOC-Epithelial|LOC / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 9.19e-05 | 199 | 20 | 3 | d64adb68502be596ce55fb2cb63fe1cfa2c5f8ba | |
| ToppCell | NS-moderate-d_16-33-Epithelial|d_16-33 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 9.19e-05 | 199 | 20 | 3 | aa2b51940115c22768c0d7493b4b60d41df3f376 | |
| ToppCell | distal-2-Epithelial|2 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 9.33e-05 | 200 | 20 | 3 | 2fc1e95706f212bf18ecdf6eb5b3182ac98c9b52 | |
| ToppCell | 5'-Airway_Nasal-Epithelial-Epithelial_transtional-secretory|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 9.33e-05 | 200 | 20 | 3 | b68d212159b9d04866ba02ff55c35be247805eec | |
| ToppCell | Neuronal-Inhibitory-iA-iA_1(SST_PAX6)-SST|Neuronal / cells hierarchy compared to all cells using T-Statistic | 9.33e-05 | 200 | 20 | 3 | 53d5e427f0cbf5cf0b63efe4ec01da302f555704 | |
| ToppCell | Neuronal-Inhibitory-iA-iA_1(SST_PAX6)-SST-MC4R|Neuronal / cells hierarchy compared to all cells using T-Statistic | 9.33e-05 | 200 | 20 | 3 | c1797542541747b524c9c22c723d24c8d027d486 | |
| ToppCell | Tracheal-10x5prime-Epithelial|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 9.33e-05 | 200 | 20 | 3 | efd461c687155c84ef590352207e6fe4ba392a90 | |
| ToppCell | distal-Epithelial|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 9.33e-05 | 200 | 20 | 3 | 0a97080f694738bb882787cee21b91a4d5757b7a | |
| ToppCell | Neuronal-Inhibitory-iA-iA_1(SST_PAX6)-SST-MC4R-L1-2|Neuronal / cells hierarchy compared to all cells using T-Statistic | 9.33e-05 | 200 | 20 | 3 | a0cc84add181109bb66ba9d49c732e1790222c96 | |
| Drug | butamben | 1.10e-05 | 6 | 20 | 2 | ctd:C004605 | |
| Drug | irinotecan HCl; Down 200; 100uM; MCF7; HT_HG-U133A | 1.77e-05 | 183 | 20 | 4 | 7498_DN | |
| Drug | Ketanserin tartrate hydrate [83846-83-7]; Up 200; 7uM; HL60; HG-U133A | 2.41e-05 | 198 | 20 | 4 | 1593_UP | |
| Drug | 2-(3-hydroxypropoxy)-1,25-dihydroxyvitamin D3 | 4.01e-05 | 11 | 20 | 2 | ctd:C061137 | |
| Drug | dihydroxy-vitamin D3 | 5.68e-05 | 13 | 20 | 2 | ctd:C118756 | |
| Drug | N-methylmorpholine | 8.11e-05 | 97 | 20 | 3 | CID000007972 | |
| Drug | ferutinin | 8.73e-05 | 16 | 20 | 2 | CID000354654 | |
| Drug | 3-hydroxyflavone | 2.93e-04 | 29 | 20 | 2 | ctd:C041477 | |
| Drug | xanthan | 4.54e-04 | 36 | 20 | 2 | CID000007107 | |
| Drug | geldanamycin; Up 200; 1uM; MCF7; HG-U133A | 5.18e-04 | 182 | 20 | 3 | 593_UP | |
| Drug | Asbestos, Crocidolite | 5.18e-04 | 1241 | 20 | 6 | ctd:D017638 | |
| Drug | Betamethasone [378-44-9]; Up 200; 10.2uM; HL60; HG-U133A | 5.27e-04 | 183 | 20 | 3 | 1590_UP | |
| Drug | testosterone-3-carboxymethyloxime-bovine serum albumin conjugate | 5.43e-04 | 185 | 20 | 3 | ctd:C045037 | |
| Drug | medrol | 5.52e-04 | 186 | 20 | 3 | CID000004159 | |
| Drug | Harmaline hydrochloride dihydrate [6027-98-1]; Down 200; 14uM; MCF7; HT_HG-U133A | 5.70e-04 | 188 | 20 | 3 | 2805_DN | |
| Drug | Corticosterone [50-22-6]; Up 200; 11.6uM; HL60; HT_HG-U133A | 5.78e-04 | 189 | 20 | 3 | 1307_UP | |
| Drug | Acetohexamide [968-81-0]; Up 200; 12.4uM; PC3; HT_HG-U133A | 6.05e-04 | 192 | 20 | 3 | 1829_UP | |
| Drug | 11-deoxy-16,16-dimethyl Prostaglandin E2; Down 200; 10uM; PC3; HT_HG-U133A | 6.24e-04 | 194 | 20 | 3 | 7538_DN | |
| Drug | Oxolinic acid [14698-29-4]; Up 200; 15.4uM; HL60; HG-U133A | 6.33e-04 | 195 | 20 | 3 | 1419_UP | |
| Drug | Hippeastrine hydrobromide [22352-41-6]; Down 200; 10uM; HL60; HT_HG-U133A | 6.33e-04 | 195 | 20 | 3 | 2187_DN | |
| Drug | Propoxycaine hydrochloride [550-83-4]; Up 200; 12uM; PC3; HT_HG-U133A | 6.43e-04 | 196 | 20 | 3 | 7155_UP | |
| Drug | Oxamniquine [21738-42-1]; Down 200; 14.4uM; HL60; HT_HG-U133A | 6.43e-04 | 196 | 20 | 3 | 2924_DN | |
| Drug | Hydroxyzine dihydrochloride [2192-20-3]; Down 200; 9uM; MCF7; HT_HG-U133A | 6.43e-04 | 196 | 20 | 3 | 1524_DN | |
| Drug | Buflomedil hydrochloride [35543-24-9]; Down 200; 11.6uM; HL60; HT_HG-U133A | 6.43e-04 | 196 | 20 | 3 | 1338_DN | |
| Drug | Epicatechin-(-) [154-23-4]; Down 200; 13.8uM; HL60; HT_HG-U133A | 6.43e-04 | 196 | 20 | 3 | 2160_DN | |
| Drug | ChEs | 6.48e-04 | 43 | 20 | 2 | CID000066898 | |
| Drug | Moroxidine hydrochloride [3160-91-6]; Down 200; 19.2uM; MCF7; HT_HG-U133A | 6.52e-04 | 197 | 20 | 3 | 5304_DN | |
| Drug | Sulfachloropyridazine [80-32-0]; Down 200; 14uM; PC3; HT_HG-U133A | 6.52e-04 | 197 | 20 | 3 | 3769_DN | |
| Drug | Etofenamate [30544-47-9]; Down 200; 10.8uM; PC3; HT_HG-U133A | 6.52e-04 | 197 | 20 | 3 | 3989_DN | |
| Drug | E)-4-hydroxytamoxifen | 6.52e-04 | 197 | 20 | 3 | CID000063062 | |
| Drug | 16, 16-dimethylprostaglandin E2 methyl acetate solution; Down 200; 10uM; MCF7; HT_HG-U133A | 6.52e-04 | 197 | 20 | 3 | 6597_DN | |
| Drug | Azaperone [1649-18-9]; Down 200; 12.2uM; MCF7; HT_HG-U133A | 6.52e-04 | 197 | 20 | 3 | 7231_DN | |
| Drug | Ketotifen fumarate [34580-14-8]; Up 200; 9.4uM; MCF7; HT_HG-U133A | 6.52e-04 | 197 | 20 | 3 | 7199_UP | |
| Drug | Carisoprodol [78-44-4]; Down 200; 15.4uM; HL60; HT_HG-U133A | 6.52e-04 | 197 | 20 | 3 | 1314_DN | |
| Drug | Mephenesin [59-47-2]; Up 200; 22uM; HL60; HT_HG-U133A | 6.62e-04 | 198 | 20 | 3 | 2342_UP | |
| Drug | Phenelzine sulfate [156-51-4]; Up 200; 17uM; PC3; HT_HG-U133A | 6.62e-04 | 198 | 20 | 3 | 3802_UP | |
| Drug | Drofenine hydrochloride [548-66-3]; Down 200; 11.4uM; HL60; HT_HG-U133A | 6.62e-04 | 198 | 20 | 3 | 2714_DN | |
| Drug | Telenzepine dihydrochloride [147416-96-4]; Up 200; 9uM; HL60; HT_HG-U133A | 6.72e-04 | 199 | 20 | 3 | 2388_UP | |
| Drug | LY 294002; Up 200; 10uM; HL60; HT_HG-U133A | 6.72e-04 | 199 | 20 | 3 | 6186_UP | |
| Drug | nordihydroguaiaretic acid; Down 200; 1uM; HL60; HT_HG-U133A | 6.72e-04 | 199 | 20 | 3 | 2683_DN | |
| Drug | estradiol, USP; Down 200; 0.01uM; MCF7; HT_HG-U133A | 6.82e-04 | 200 | 20 | 3 | 1666_DN | |
| Drug | Acenocoumarol [152-72-7]; Up 200; 11.4uM; PC3; HT_HG-U133A | 6.82e-04 | 200 | 20 | 3 | 2077_UP | |
| Drug | Androstenedione | 7.09e-04 | 45 | 20 | 2 | ctd:D000735 | |
| Drug | 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane | 7.43e-04 | 206 | 20 | 3 | ctd:C404910 | |
| Drug | panobinostat | 7.58e-04 | 1333 | 20 | 6 | ctd:C496932 | |
| Drug | UF-1 | 7.74e-04 | 47 | 20 | 2 | CID000008572 | |
| Drug | glyphosate | 8.41e-04 | 215 | 20 | 3 | CID000003496 | |
| Disease | alveolar rhabdomyosarcoma (is_implicated_in) | 1.31e-06 | 3 | 20 | 2 | DOID:4051 (is_implicated_in) | |
| Disease | Alveolar rhabdomyosarcoma | 1.31e-06 | 3 | 20 | 2 | cv:C0206655 | |
| Disease | RHABDOMYOSARCOMA 2 | 1.31e-06 | 3 | 20 | 2 | 268220 | |
| Disease | Alveolar rhabdomyosarcoma | 4.36e-06 | 5 | 20 | 2 | C0206655 | |
| Disease | prostate cancer (is_marker_for) | 1.55e-04 | 156 | 20 | 3 | DOID:10283 (is_marker_for) | |
| Disease | Breast adenocarcinoma | 3.52e-04 | 41 | 20 | 2 | C0858252 | |
| Disease | Neoplasm of uncertain or unknown behavior of breast | 3.52e-04 | 41 | 20 | 2 | C0496956 | |
| Disease | Breast Carcinoma | 4.20e-04 | 538 | 20 | 4 | C0678222 | |
| Disease | Prostatic Neoplasms | 6.98e-04 | 616 | 20 | 4 | C0033578 | |
| Disease | Malignant neoplasm of prostate | 6.98e-04 | 616 | 20 | 4 | C0376358 | |
| Disease | cannabis dependence | 3.74e-03 | 135 | 20 | 2 | EFO_0007191 | |
| Disease | lung non-small cell carcinoma (is_implicated_in) | 3.96e-03 | 139 | 20 | 2 | DOID:3908 (is_implicated_in) | |
| Disease | stomach cancer (is_marker_for) | 4.13e-03 | 142 | 20 | 2 | DOID:10534 (is_marker_for) |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| PAGSSMGTYHNNMTT | 226 | Q9UMD9 | |
| GLMASSSPYSQPMNN | 1041 | Q8NFD5 | |
| PNQQMSPSPMSHGHY | 26 | P56177 | |
| YSDSFMNPAAPSNHM | 361 | P23759 | |
| HSMNGFMYGNQPGLT | 621 | P00450 | |
| YSTTPTSQPGMYNMS | 861 | Q96JK9 | |
| GVSCSMSPAMYQAHP | 111 | Q8N8A8 | |
| MSPAMYQAHPGNSED | 116 | Q8N8A8 | |
| SGNMTPASFNMSYAN | 56 | P55317 | |
| TYGSQASHNKMMNPS | 506 | Q12778 | |
| YANNHPSMHMGQPSC | 1126 | O75976 | |
| MNGHISNHPSSFGMY | 1 | Q12929 | |
| SNHPSSFGMYPSQMN | 6 | Q12929 | |
| MAAQYGSMSFNPSTP | 1 | Q9NUV9 | |
| FHLQGQSPSFNSMMN | 1126 | Q9Y6Q9 | |
| STGMNYTPSMHQEAQ | 16 | Q86UD5 | |
| NANYSSMPSPDMDPA | 466 | Q17R89 | |
| GNTHGMPCMFPFQYN | 171 | Q13018 | |
| GSYSPMQDPNFHTMG | 1146 | Q15596 | |
| MQDPNFHTMGQRPSY | 1151 | Q15596 | |
| MGGNSMFSQQSPPHF | 1361 | Q15596 | |
| SPPHFGQQANTSMYS | 1371 | Q15596 | |
| AAGAQFPNYSPMNMN | 211 | O60481 | |
| MPSPGDSTNSSENMY | 276 | Q9BWG4 | |
| PMQTYPVQSHGGNYM | 391 | O75886 | |
| GTQYSSHPQMAAMRP | 146 | O94900 |